Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.20

€0.20

-3.330%
-0.007
-3.330%
€3.00

€3.00

 
01.12.21 / Tradegate WKN: A2QHTZ / Name: Juva Life Inc. / Stock / ? /
Latest predictions
€5.00
21.06.21
-40.03%
buy
€3.00
23.04.21
-70.37%
buy
€3.00
04.02.21
-82.84%
buy
€3.00
30.01.21
-81.90%
buy
Your prediction

Juva Life Inc. Stock

Heavy losses for Juva Life Inc. today as the stock fell by -€0.007 (-3.330%).
Currently there is a rather positive sentiment for Juva Life Inc. with 4 Buy predictions and 0 Sell predictions.
Based on the current price of €0.20 the target price of €3.00 shows a potential of 1413.623% for Juva Life Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Juva Life Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Juva Life Inc. in the next few years

Pros
1
Could be very worthwhile Investment >20% year
Cons
0
-

Other discussions about Juva Life Inc. Stock

New thread Forum

News

Juva Life Launches Preclinical Comparative Study to Evaluate Anti-Inflammatory Properties of Candidate JUVA-019 in Conjunction With Other Well-Known Cannabinoids

Cannabis and Life Sciences Company Initiates Internal Study Comparing Anti-Inflammatory Properties of Candidate JUVA-019 When Combined With Cannabinoids Such as THC and CBD

 

VANCOUVER,

Juva Life Identifies Second Molecular Compound Found in Cannabis With Significant Anti-Inflammatory Therapeutic Properties Coined JUVA-041

Cannabis and Life Sciences Company Adds Second Novel Non-Cannabinoid Compound to Pharmaceutical Pipeline

 

VANCOUVER, British Columbia, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE:

Juva Life Files Patent on Family of Non-Cannabinoid Small Molecules Targeting Consumer and Pharma Inflammatory Indications

VANCOUVER, BC, -- October 14, 2021) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a California based life sciences company focused on